OpGen latest IPO hopeful with $35m filing
This article was originally published in Clinica
Executive Summary
OpGen, which specializes in molecular tests for multi-drug-resistant bacterial infections, has become the latest medtech firm to file for an initial public offering. This brings the total filings tracked by Clinica to 12 in 2015 so far – with three of these completed.